Patents by Inventor Joseph C. Wu
Joseph C. Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786503Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: October 7, 2021Date of Patent: October 17, 2023Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20230321077Abstract: Treatment of dilated cardiomyopathy in a subject by combination treatment with a tyrosine kinase inhibitor and a statin.Type: ApplicationFiled: April 10, 2023Publication date: October 12, 2023Applicant: GreenStone Biosciences, Inc.Inventors: Joseph C. Wu, Chun Liu, Christopher David Yan, Celine Lai
-
Publication number: 20230032239Abstract: The present invention includes methods for treating and/or preventing dilated cardiomyopathy due to an LMNA mutation, comprised of administering to a subject at-risk a therapeutically effective amount of an inhibitor of PDGF signaling.Type: ApplicationFiled: January 15, 2020Publication date: February 2, 2023Inventors: Vittavat Termglinchan, Ioannis Karakikes, Joseph C. Wu, Jaecheol Lee, Sebastian Diecke
-
Publication number: 20220348877Abstract: Human cardiac fibroblasts obtained from induced pluripotent stem cells (iPS cells) are provided for use in analysis, screening programs, and the like.Type: ApplicationFiled: June 26, 2020Publication date: November 3, 2022Inventors: Joseph C. Wu, Hao Zhang
-
Publication number: 20220273591Abstract: Compositions, methods, and kits are provided for determining whether a subject is at risk of developing insulin resistance. In particular, phosphorylated Akt, reactive oxygen species (ROS), SIRT1, eNOS, CDH13, IRS1 and NO production have been identified as biomarkers associated with insulin resistance and type 2 diabetes. The diagnostic methods comprise measuring the level of at least one biomarker in induced pluripotent stem cells derived from somatic cells of the subject, which have been differentiated into endothelial cells (IPSC-ECs).Type: ApplicationFiled: July 24, 2020Publication date: September 1, 2022Inventors: Joseph C. Wu, Edward Lau, Mark Chandy
-
Publication number: 20220133684Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: October 7, 2021Publication date: May 5, 2022Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Patent number: 11298380Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.Type: GrantFiled: January 1, 2019Date of Patent: April 12, 2022Assignees: Khloris Biosciences, Inc., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Nigel G. Kooreman, Joseph C. Wu, Lynne A. Bui
-
Patent number: 11166936Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: October 6, 2020Date of Patent: November 9, 2021Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20210121436Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: October 6, 2020Publication date: April 29, 2021Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Publication number: 20210047710Abstract: Implementations of the disclosure are directed to improving the ductility of a tin-enriched AuSn solder alloy by doping the solder alloy with Germanium (Ge). The final AuSnGe alloy may consist of 75 to 80 wt % Au, 20 to 25 wt % Sn, and 0.05 to 1.5 wt % Ge.Type: ApplicationFiled: August 16, 2019Publication date: February 18, 2021Inventors: Joseph C. Wu, Christopher Testa, Carmen Salvatore, Brian Reid
-
Patent number: 10874633Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: January 8, 2020Date of Patent: December 29, 2020Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Patent number: 10806716Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: February 3, 2017Date of Patent: October 20, 2020Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20200253920Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: January 8, 2020Publication date: August 13, 2020Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Publication number: 20200121728Abstract: In the context of a stem cell-based therapy in which differentiated cells are derived from pluripotent stem cells, this application discloses approaches for eliminating residual pluripotent stem cells that may remain in a batch of differentiated progeny cells. This advantageously prevents the formation of teratoma tumors when the differentiated cells are eventually used for the therapy. This can be accomplished by exposing the batch of differentiated progeny cells and the residual pluripotent stem cells to an alternating electric field for a period of time. The frequency and field strength of the alternating electric field are such that the pluripotent stem cells die off as a result of exposure to the alternating electric fields, while the differentiated cells remain substantially unharmed. This results in a purified batch of differentiated progeny cells that is rendered safe for use in the stem cell-based therapy.Type: ApplicationFiled: October 23, 2019Publication date: April 23, 2020Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mirwais WARDAK, Edwin CHANG, Joseph C. WU, Sanjiv Sam GAMBHIR
-
Publication number: 20190290697Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.Type: ApplicationFiled: January 1, 2019Publication date: September 26, 2019Applicants: Khloris Biosciences, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Nigel G. Kooreman, Joseph C. Wu, Lynne A. Bui
-
Publication number: 20190175544Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: February 3, 2017Publication date: June 13, 2019Applicants: SCT II LLC, Auransa Inc.Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20170224654Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: February 3, 2017Publication date: August 10, 2017Applicants: Stem Cell Theranostics, Inc., Capella Biosciences, Inc.Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Patent number: 8680064Abstract: Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor—lot (HIF-1 ?) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1? and asparaginyl hydroxylase genes. The vectors encoding shRNA are also useful for the treatment of cardiac diseases, peripheral vascular diseases and decubitis ulcers.Type: GrantFiled: September 15, 2009Date of Patent: March 25, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Joseph C. Wu, Mei Huang, Amato J. Giaccia, Denise Chan
-
Publication number: 20120004283Abstract: Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor—lot (HIF-1 ?) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1? and asparaginyl hydroxylase genes. The vectors encoding shRNA are also useful for the treatment of cardiac diseases, peripheral vascular diseases and decubitis ulcers.Type: ApplicationFiled: September 15, 2009Publication date: January 5, 2012Applicant: The Board of Trustees of the Leland Stanford JunioInventors: Joseph C. Wu, Amato John Giaccia, Mei Huang, Denise A. Chan
-
Patent number: RE34540Abstract: A frequency modulated ratio frequency broadcast network in which re-transmitting stations employ a synchronous frequency modulated booster system. Included in the frequency modulated booster system is a synchronous frequency modulated exciter for converting a frequency modulated intermediate frequency into a frequency modulated broadcast signal. The synchronous frequency modulated exciter includes phase locked loop circuits for synchronizing the re-transmitted frequency modulated broadcast signal with the frequency modulated intermediate frequency signal by detecting reference signals in the composite baseband of the intermediate frequency signal and in the composite signal frequency modulated broadcast signal.Type: GrantFiled: April 3, 1992Date of Patent: February 8, 1994Assignee: TFT, Inc.Inventors: Joseph C. Wu, Charlie L. Hu, Yee S. Law